Thomas E. Seay

10.7k total citations · 1 hit paper
20 papers, 2.2k citations indexed

About

Thomas E. Seay is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Thomas E. Seay has authored 20 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in Thomas E. Seay's work include Cancer Treatment and Pharmacology (7 papers), Estrogen and related hormone effects (6 papers) and HER2/EGFR in Cancer Research (6 papers). Thomas E. Seay is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Estrogen and related hormone effects (6 papers) and HER2/EGFR in Cancer Research (6 papers). Thomas E. Seay collaborates with scholars based in United States, Canada and Ireland. Thomas E. Seay's co-authors include Norman Wolmark, Greg Yothers, Louis Fehrenbacher, Linda H. Colangelo, Michael J. O’Connell, Nicholas J. Petrelli, Eleftherios P. Mamounas, James N. Atkins, Charles E. Geyer and Priya Rastogi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Thomas E. Seay

20 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

2005 568 citations Elizabeth Tan-Chiu, Greg Yothers et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas E. Seay United States	15	1.7k	558	502	361	308	20	2.2k
Frank A. Scappaticci United States	22	1.4k 0.8×	470 0.8×	856 1.7×	261 0.7×	211 0.7×	38	2.8k
P Soulié France	25	1.7k 1.0×	394 0.7×	761 1.5×	300 0.8×	312 1.0×	118	2.3k
Hans‐Joachim Lück Germany	28	1.9k 1.1×	721 1.3×	572 1.1×	96 0.3×	272 0.9×	67	2.9k
Christian Rothermundt Switzerland	25	1.0k 0.6×	371 0.7×	971 1.9×	191 0.5×	197 0.6×	79	2.3k
Marianne Krahn Canada	3	1.3k 0.7×	198 0.4×	526 1.0×	338 0.9×	304 1.0×	6	1.8k
Wei‐Xiang Qi China	24	1.1k 0.7×	227 0.4×	940 1.9×	310 0.9×	153 0.5×	109	2.1k
Giuseppe Fraschini United States	23	1.4k 0.8×	933 1.7×	319 0.6×	293 0.8×	428 1.4×	53	2.1k
D. Fennelly Ireland	25	1.8k 1.0×	377 0.7×	564 1.1×	83 0.2×	332 1.1×	85	2.6k
Massimo Lopez Italy	21	1.6k 0.9×	516 0.9×	598 1.2×	105 0.3×	213 0.7×	59	2.2k
S. Tjulandin Russia	20	1.4k 0.8×	724 1.3×	596 1.2×	57 0.2×	238 0.8×	75	2.1k

Countries citing papers authored by Thomas E. Seay

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Seay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Seay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Seay more than expected).

Fields of papers citing papers by Thomas E. Seay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Seay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Seay. The network helps show where Thomas E. Seay may publish in the future.

Co-authorship network of co-authors of Thomas E. Seay

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Seay. A scholar is included among the top collaborators of Thomas E. Seay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Seay. Thomas E. Seay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Mamounas, Eleftherios P., Hanna Bandos, Barry C. Lembersky, et al.. (2020). Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). Cancer Research. 80(4_Supplement). GS4–1. 12 indexed citations

2.

Mamounas, Eleftherios P., Hanna Bandos, Barry C. Lembersky, et al.. (2018). Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 20(1). 88–99. 99 indexed citations

3.

Ganz, Patricia A., Edward H. Romond, Reena S. Cecchini, et al.. (2017). Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. Journal of Clinical Oncology. 35(35). 3942–3948. 49 indexed citations

4.

Ganz, Patricia A., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet. 387(10021). 857–865. 59 indexed citations

5.

Margolese, Richard G., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet. 387(10021). 849–856. 127 indexed citations

6.

Margolese, Richard G., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. Journal of Clinical Oncology. 33(15_suppl). LBA500–LBA500. 1 indexed citations

7.

Margolese, Richard G., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. Journal of Clinical Oncology. 33(18_suppl). LBA500–LBA500. 8 indexed citations

8.

Siziopikou, Kalliopi P., Stewart Anderson, Melody Cobleigh, et al.. (2013). Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Research and Treatment. 142(2). 415–421. 45 indexed citations

9.

Hoff, Daniel D. Von, Thomas J. Ervin, Francis P. Arena, et al.. (2013). Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. Journal of Clinical Oncology. 31(4_suppl). LBA148–LBA148. 90 indexed citations

10.

Hoff, Daniel D. Von, Thomas J. Ervin, Francis P. Arena, et al.. (2013). Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.. Journal of Clinical Oncology. 31(15_suppl). 4005–4005. 32 indexed citations

11.

Alberts, Steven R., Joel M. Reid, Bruce W. Morlan, et al.. (2011). Gemcitabine and Docetaxel for Hepatocellular Carcinoma. American Journal of Clinical Oncology. 35(5). 418–423. 14 indexed citations

12.

Allegra, Carmen J., Greg Yothers, Michael J. O’Connell, et al.. (2010). Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. Journal of Clinical Oncology. 29(1). 11–16. 410 indexed citations

13.

Moinpour, Carol M., Nancy L. Vaught, Bryan Goldman, et al.. (2010). Pain and Emotional Well-Being Outcomes in Southwest Oncology Group–Directed Intergroup Trial S0205: A Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine As First-Line Therapy in Patients With Advanced Pancreas Cancer. Journal of Clinical Oncology. 28(22). 3611–3616. 18 indexed citations

14.

Allegra, Carmen J., Greg Yothers, Michael J. O’Connell, et al.. (2009). Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. Journal of Clinical Oncology. 27(20). 3385–3390. 200 indexed citations

15.

Kuebler, J. Philip, Linda H. Colangelo, Michael J. O’Connell, et al.. (2007). Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin. Cancer. 110(9). 1945–1950. 32 indexed citations

16.

Land, Stephanie R., Jacek A Kopec, Reena S. Cecchini, et al.. (2007). Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07. Journal of Clinical Oncology. 25(16). 2205–2211. 184 indexed citations

17.

Lembersky, Barry C., H. Samuel Wieand, Nicholas J. Petrelli, et al.. (2006). Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Journal of Clinical Oncology. 24(13). 2059–2064. 239 indexed citations

18.

Tan-Chiu, Elizabeth, Greg Yothers, Edward H. Romond, et al.. (2005). Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31. Journal of Clinical Oncology. 23(31). 7811–7819. 568 indexed citations breakdown →

19.

Scott, Charles, James E. Marks, Thomas E. Seay, et al.. (2002). Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin e1 analog misoprostol (RTOG 96-07). International Journal of Radiation Oncology*Biology*Physics. 54(5). 1455–1459. 12 indexed citations

20.

Schroder, Louis E., Danika L. Lew, Robert C. Flanigan, et al.. (2001). Phase II evaluation of suramin in advanced renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 6(4). 145–148. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact